Status:
NOT_YET_RECRUITING
JAM3 as a Prognostic Biomarker in Muscle-Invasive Urothelial Carcinoma: Correlation With Therapeutic Response, and Survival Outcomes
Lead Sponsor:
Zeinab Yahia Zaki
Conditions:
Urothelial Carcinoma Bladder
Eligibility:
All Genders
18+ years
Brief Summary
Bladder cancer(BC) is the 10th most common cancer globally, with a higher incidence in males than females, being the 6th most common cancer in men with high mortality, causing a societal burden worldw...
Eligibility Criteria
Inclusion
- Inclusion criteria
- Patients above 18 years
- Histopathological confirmed TCC
- Patients with MIBC
- Patients eligible for neoadjuvant chemotherapy
- Exclusion criteria
- Patients with metastatic disease
- Patients ineligible for systemic therapy
Exclusion
Key Trial Info
Start Date :
October 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2028
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06901934
Start Date
October 1 2025
End Date
October 1 2028
Last Update
March 30 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.